KineMed, Inc. Receives an Investigator-Initiated Study Grant From Daiichi Sankyo Co Ltd. to Further Explore Mechanism(s) of Action Associated with Welchol(R) (colesevelam HCl) in Type 2 Diabetes Mellitus

EMERYVILLE, Calif.--(BUSINESS WIRE)--KineMed, Inc., a translational and personalized medicine development company, announced today that the company has received an investigator initiated study grant from Daiichi Sankyo, Inc. to conduct a clinical study designed to better understand and characterize the beneficial effects of Welchol® (colesevelam HCl) in patients with Type 2 Diabetes Mellitus (T2DM).